Dermalogica Aarhus ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  17.8% 9.0% 7.6% 12.7% 8.2%  
Credit score (0-100)  9 27 31 18 29  
Credit rating  B BB BB BB BB  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,441 1,033 1,612 1,535 1,947  
EBITDA  -384 -607 163 30.4 465  
EBIT  -384 -652 -258 -404 28.4  
Pre-tax profit (PTP)  -384.6 -653.4 -263.5 -416.1 29.2  
Net earnings  -300.0 -509.6 -205.6 -324.5 22.6  
Pre-tax profit without non-rec. items  -385 -653 -264 -416 29.2  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 1,850 1,474 1,163 770  
Shareholders equity total  -367 -877 -1,082 -1,407 -1,384  
Interest-bearing liabilities  476 3,156 3,604 2,660 3,077  
Balance sheet total (assets)  976 3,059 3,384 1,999 2,702  

Net Debt  82.7 2,930 2,303 2,425 1,838  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,441 1,033 1,612 1,535 1,947  
Gross profit growth  2.1% -28.3% 56.0% -4.8% 26.9%  
Employees  6 5 5 5 5  
Employee growth %  -14.3% -16.7% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  976 3,059 3,384 1,999 2,702  
Balance sheet change%  11.8% 213.4% 10.6% -40.9% 35.2%  
Added value  -383.8 -607.2 162.6 16.9 465.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 2,014 -841 -789 -873  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -26.6% -63.1% -16.0% -26.3% 1.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -33.6% -24.7% -6.1% -10.3% 0.8%  
ROI %  -119.2% -34.6% -7.4% -12.6% 1.0%  
ROE %  -32.4% -25.3% -6.4% -12.1% 1.0%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -40.8% -25.1% -26.8% -46.2% -36.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -21.6% -482.6% 1,415.7% 7,972.5% 395.2%  
Gearing %  -129.5% -359.9% -333.0% -189.1% -222.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.3% 0.1% 0.2% 0.4% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.6 0.2 0.3 0.1 0.4  
Current Ratio  0.6 0.2 0.4 0.2 0.4  
Cash and cash equivalent  392.8 225.2 1,301.4 234.9 1,239.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -594.5 -2,898.1 -2,728.4 -2,699.8 -2,256.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -64 -121 33 3 93  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -64 -121 33 6 93  
EBIT / employee  -64 -130 -52 -81 6  
Net earnings / employee  -50 -102 -41 -65 5